Correspondingly, treatment of lung cancers bearing EGFR mutations with EGFR tyrosine kinase inhibitors Gefitinib and Erlotinib has been shown to be much more effective than chemotherapy7–9. This evidence concerns the gene EGFR and lung cancer.